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Abstract
Background
Cognitive and visual impairments are common in Parkinson’s disease (PD) and
contribute to gait deficit and falls. To date, cognition and vision in gait in PD
have been assessed separately. Impact of both functions (which we term
‘visuo-cognition’) on gait however is likely interactive and can be tested using
visual sampling (specifically saccadic eye movements) to provide an online
behavioural measure of performance. Although experiments using static
paradigms show saccadic impairment in PD, few studies have quantified visual
sampling during dynamic motor tasks such as gait.
This article describes a protocol developed for testing visuo-cognition during
gait in order to examine the: 1) independent roles of cognition and vision in gait
in PD, 2) interaction between both functions, and 3) role of visuo-cognition in
gait in PD.
Methods 
Two groups of older adults (≥50 years old) were recruited; non-demented
people with PD (n=60) and age-matched controls (n=40). Participants attended
one session and a sub-group (n=25) attended two further sessions in order to
establish mobile eye-tracker reliability. Participants walked in a gait laboratory
under different attentional (single and dual task), environmental (walk straight,
through a door and turning), and cueing (no visual cues and visual cues)
conditions. Visual sampling was recorded using synchronised mobile
eye-tracker and electrooculography systems, and gait was measured using 3D
motion analysis.
Discussion 
This exploratory study examined visuo-cognitive processes and their impact on
gait in PD. Improved understanding of the influence of cognitive and visual
functions on visual sampling during gait and gait in PD will assist in
development of interventions to improve gait and reduce falls risk. This study
will also help establish robust mobile eye-tracking methods in older adults and
people with PD.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative disease1 
characterised by the death and dysfunction of dopaminergic neu-
rons in the substantia nigra2. PD causes progressive motor symp-
toms such as problems with gait3 and non-motor symptoms such as 
visual and cognitive impairment1. Cognitive impairment is common 
in PD with reports of dementia ranging up to ~80%4, and may occur 
early in the disease process5. Visual dysfunction is also common in 
people with PD, with up to 78% of people with PD reporting at least 
one visual problem6. Gait impairment in PD is complex, involving 
multi-system dysfunction and has been widely related to cognitive, 
and to a lesser extent visual deficits. A more robust understand-
ing of these complex processes and their interactions will inform 
underlying mechanisms of gait impairment in PD, which may pro-
vide insight for future therapeutic intervention. Interventions, such 
as visual cues (prompts; transverse tape lines to step over) are cur-
rently used to ameliorate features of gait disturbance in PD resist-
ant to dopaminergic medication, such as festination, hesitation and 
freezing of gait7,8. However, visual cue response is selective9 and the 
mechanisms that contribute to the response are unclear.
To date, associative (correlational) and online manipulation (via 
dual tasks and environmental changes) studies have investigated 
the independent contribution of cognition and vision in gait in PD. 
However, cognitive and visual functions likely interact and have a 
combined - impact on gait in PD. Recent technological progress 
has enabled the monitoring of online visuo-cognition through 
behavioural outcomes such as visual sampling which reflects both 
visual10,11 and cognitive12–14 processes. Visual sampling is the com-
bination of saccadic fast eye-movements and fixations (pauses 
between saccades on areas of interest) made during real-world 
activities15. However, research is compromised by several techno-
logical limitations which need to be addressed to ensure robust data 
collection and analysis. For example, there is currently no ‘gold 
standard’ visual sampling measurement device or outcome measure 
and there is also a lack of device accuracy or reliability reporting in 
all previous studies15.
Visual sampling (specifically saccades) allow orientation to the 
visual environment bringing areas of interest into high visual acu-
ity (foveation or focus)16. Saccades are impaired in PD and exhibit 
reduced speed, amplitudes and latencies17–22. Impaired saccadic eye 
movements, with reduced latencies and increased error rates have 
also been reported in PD dementia and dementia with Lewy Bodies, 
further implicating central neuro-degeneration as a determinant of 
ocular motor function23,24. However, the specific contribution of cog-
nitive and/or visual functions to visual sampling during gait in PD 
and how this impacts gait deficit is currently poorly understood.
Much of the previous saccadic activity research is limited due to the 
almost exclusive use of static testing protocols (e.g. computerised 
tasks in sitting)18,25, which may not be applicable to real-world situ-
ations. A recent review of dynamic motor tasks (e.g. gait, obstacle 
crossing, turning etc.) in PD and older adults15, demonstrated that 
visual sampling is task dependent and relates to specific goals26. 
For example: during locomotion over even terrain, saccades may 
not be required. Over uneven (complex) terrain or during turning 
saccadic frequency, amplitude and fixations increase27–30. However 
many previous visual sampling protocols during dynamic task 
studies use small cohorts and often do not assess cognitive or vis-
ual functions15, which limits interpretation and conclusions regard-
ing underlying mechanisms. Visual sampling during gait therefore 
has not been fully investigated and further research is required to 
understand this important feature of gait control. Improved under-
standing will assist with interventions to improve gait performance 
in PD.
Aims
The aims of this study are to better understand: 1) the independ-
ent roles of cognition and vision in gait in PD, 2) the interaction 
between both functions (termed visuo-cognition), and 3) the role of 
visuo-cognition in gait in PD.
Secondary aims were to:
1.   Investigate accuracy and reliability of mobile eye-tracking 
during gait in people with PD and older adults
Methods/Design
Study design
We used a repeated-measures observational design of visual sam-
pling during gait. We also embedded accuracy and reliability testing 
of a mobile eye-tracker within the study. It involved 100 older adult 
participants who were separated into two groups (people with PD 
and older adult controls).
Participants and setting
Two groups of participants were recruited: i) People with idiopathic 
PD (PD) (n=60); and ii) Age-matched older adults (controls) (n=40). 
Inclusion criteria and exclusion criteria are highlighted in Table 1. 
Vision-specific criteria (identified through medical notes) were 
included due to the impact of certain conditions on eye-tracking 
capabilities. The setting for the study was the gait laboratory at the 
Clinical Ageing Research Unit (CARU), Campus for Ageing and 
Vitality, Newcastle University, United Kingdom.
Recruitment
People with PD were identified through the Movement Disorders 
Clinic at the Clinics for Research and Service in Themed Assess-
ments (CRESTA) in Newcastle upon-Tyne. Research personnel 
were available at clinics as required to invite participants to con-
sider the study. If sufficiently interested, participants were given a 
Participant Information Sheet (PIS) and letter concerning the study. 
The invitation was followed up by a telephone call during the week 
to assess willingness to participate. If willing, a mutually conven-
ient time for assessment was organised and the invitation to attend 
was extended to a carer or spouse.
The older adult control group was recruited via advertisement using 
posters placed within neurology and geriatric departments. The 
advertisement was sent via the university email system to staff and 
students at Newcastle University. Recipients were asked to pass 
on the poster to potential interested parties (i.e. family or friends). 
Participants received reimbursement of travel expenses for their 
own vehicle or for public transport, if this is preferred.
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Measures and procedures
Global cognitive assessment
Global cognition was assessed using the Montreal cognitive assess-
ment (MoCA) and Addenbrookes cognitive examination (ACE-R)37. 
The MoCA was performed during screening to exclude control par-
ticipants with cognitive impairment (MoCA <26) and PD partici-
pants with dementia (MoCA <21)5 (Table 1). The MoCA is a valid 
and standardized neuropsychological test for rapid screening of 
global cognitive dysfunction37, and assesses several different cog-
nitive domains (attention and concentration, executive functions, 
memory, language, visuo-constructional skills, conceptual think-
ing, calculations, and orientation). ACE-R has also been shown to 
be valuable in differential diagnosis of PD when compared to the 
mini-mental state examination (MMSE)38. Similar to the MoCA, 
the ACE-R involves testing multiple cognitive domains, such as; 
attention, orientation, memory, fluency, language and visuospatial 
abilities.
Specific Cognitive Domain Assessment
Attention. Attention was measured via the Cognitive Drug Research 
(CDR) battery (United Biosource Corporation, UK). This provides 
specific measures of attention, including Power of attention which 
is the sum of Simple reaction time, Digit vigilance and Choice reac-
tion time39. The attention CDR is a valid test of attention and has 
been used in a number of studies involving both PD and cognitively 
impaired individuals40. The attention CDR involves a series of com-
puterised tests, which the participants respond to by pressing one of 
two buttons (YES or NO buttons).
Executive function. Clock drawing (specifically Royall’s CLOX 1)41 
was used as a measure of executive function (i.e. planning). Clock 
drawing assessment is a measure of cognitive impairment, which is 
an internally consistent measure that is easy to administer and has 
good reliability. Participants were required to plan and draw a clock 
from memory with the numbers and arrows pointed at a particular 
time, which is then marked out of 15 for certain criteria (e.g. hour 
hand shorter than the minute hand = one point).
Working Memory. Working memory was assessed using the maxi-
mal Wechsler forward digit span42, performed while seated. The 
forward digit span is reported as a simple span test, which measures 
storage and manipulation of information by working memory43.
The forward digit span consists initially of two numbers being 
played over loud speaker at a rate of 1 per second for the participant 
to recall, and continues to a maximum of nine numbers43. Three 
trials per span length were conducted and the test continued until a 
participant fails two out of three trials. The maximal length of the 
digit span was determined, defined as the most numbers a partici-
pant could remember two out of three times without error.
Table 1. Inclusion and Exclusion Criteria.
Inclusion Criteria Exclusion Criteria
Common to all groups
• Aged ≥50 years
• Able to walk unaided
• Adequate hearing (as evaluated by the whisper test; stand 2m 
behind participant and whisper a 2 syllable word, participant 
repeats word) and vision capabilities (as measured using a 
Snellen chart – 6/18–6/12).
• Stable medication for the past 1 month and anticipated over a 
period of 6 months
Group Specific Criteria
Participants with PD:
• Diagnosis of idiopathic PD, as defined by the UK Brain Bank 
criteria31
• Hoehn and Yahr stage I–III32
• Stable medication for past 1 month and anticipated over next 
6 months or stable Deep Brain Stimulation for at least one month 
and expected following 6 months
• Score ≥21/30 on Montreal cognitive assessment (MoCA) which is 
used to classify non-demented PD (PD dementia is <21/30)33–35
• Free from any neurological disorders that may have caused 
cognitive impairment
• No restriction was made for medication usage and participants 
on stable doses of medication or treatment were permitted.
Common to all groups
• Psychiatric co-morbidity (e.g., major depressive disorder 
as determined by geriatric depression scale (GDS-15); 
>10/1536)
• Clinical diagnosis of dementia or other severe cognitive 
impairment (PD = MoCA <21/30, Controls = MoCA <26/3037)
• History of stroke, traumatic brain injury or other 
neurological disorders (other than PD, for that group)
• Acute lower back or lower extremity pain, peripheral 
neuropathy, rheumatic and orthopaedic diseases
• Unstable medical condition including cardio-vascular 
instability in the past 6 months
• Unable to comply with the testing protocol or currently 
participating in another interfering research project
• Interfering therapy
Vision Specific Criteria
• Any pupillary diameter disorder; such as significantly 
non-round pupils, Adies pupil (tonic or dilated pupil), Argyll-
Robertson pupil (absence of light reaction), unilateral small 
pupil
• Neuromotility disorders, such as Nystagmus or other ocular 
oscillations
• Significant left eye disorders (i.e. squint, twitching, Ptosis 
[drooping eyelids])
• Known significant visual field deficits; such as hemianopia
• Optic nerve disease
• Optic disc elevation
• Optic disc swelling; such as Papilledema or Papillitis
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Visuo-spatial assessment
Clock copying (specifically Royall’s CLOX 2)41 measured visuo-
spatial ability (i.e. ability to identify the spatial relationship of 
objects). Clock copying is considered a valid measure of visuo- 
spatial ability linked with right parietal pathology41,44. For CLOX 2 
the researcher draws a clock and the participant must then copy the 
clock drawn, similar to the cube copying in the MoCA.
Benton’s Judgement of Line Orientation (JLO) test was also used as 
a measure of visuo-spatial ability. The JLO test has been shown to 
be a valid and reliable measure of visuo-spatial abilities45. The JLO 
test involves a participant viewing a set of numbered lines and then 
being shown two lines of the same orientation. They then have to 
name the numbers that the shown lines correspond to.
Specific sections of the visual object and space perception (VOSP) 
battery was used for more specific visuo-spatial assessment, such 
as; incomplete letters (visual object perception), dot counting and 
position discrimination (both spatial perception). The VOSP has 
been shown to be a valid measure of visuo-spatial abilities46 and 
consists of a screening test to establish requisite sensory acuity and 
specific clinical tests47. The VOSP test has been used before in older 
adults and neurological disorder studies48–50.
Visual Function Assessment
Visual function assessment included measurement of visual acuity 
(VA) and contrast sensitivity (CS) using basic eye-charts.
Visual acuity (VA). VA was measured binocularly using a standard 
LogMAR chart51. Participants were seated at a distance of 4m from 
the chart. Participants were instructed to read aloud down the chart 
starting from the top left. All correct answers are recorded on a 
pre-set score sheet. The test is terminated if the participant makes 
two consecutive errors52. Assessment was done for each eye and 
binocularly.
Contrast sensitivity (CS). CS was measured using the Mars CS 
sheets (Mars letter CS chart, Mars Percetrix™, New York, USA) 
placed on an adjustable holder53. The sheet consists of 48 Latin 
letters of uniform height; the contrast from the white background 
decreases with subsequent letters. Room illumination was adjusted 
so that average CS sheet luminance was between 80 and 120cd/m² 
(measured via a luminance meter). Assessment was done for each 
eye and binocularly with the average distance from the participants 
eyes being 50cm. Participants read aloud down the sheet starting 
at the top left. Errors were recorded on the pre-set score sheet and 
testing was terminated after two consecutive errors.
Parkinson’s disease-specific assessment
The Unified Parkinson’s disease Rating Scale (UPDRS). The 
Unified Parkinson’s Disease Rating Scale54 (Movement Disorder 
Society revised version) was used to assess motor and non-motor 
features of PD and disease severity. The UPDRS was scored from a 
total of 195 points; higher scores reflect worsening disability.
Hoehn & Yahr (H & Y). The Hoehn and Yahr rating scale55 is a 
widely used clinical rating scale, which defines broad categories 
of motor function in PD. Only PD participants with mild to moder-
ately severe motor function (H&Y stages I–III) were included.
The FOG questionnaire (FOGQ). Freezing of gait (FOG) was 
evaluated using the FOG questionnaire56,57. This is a ten-item ques-
tionnaire intended to classify FOG. The questionnaire has three 
parts; distinction of freezers from non-freezers, freezing severity, 
frequency and duration and impact of freezing on daily life.
Assessments common to both groups
The Geriatric Depression Scale (GDS-15) short form. The geriatric 
depression scale (GDS-15) short form54,55 was used to evaluate par-
ticipant depression. The GDS-15 was created in 1986 by Sheikh and 
Yesavage and involves 15 questions about the mood of participants56. 
The GDS-15 classifies depression via the following scores; 0 to 4 
indicates a normal range, 5 to 9 indicates mild depression, and 10 to 
15 indicates moderate to severe depression57.
Falls Efficacy Scale – International version (FES-I). Fear of 
falling was measured using the falls efficacy scale – international 
version (FES-I). This is a short validated measure of fear of falling 
in older adults, which assesses basic and demanding activities (both 
physical and social)58. It consists of 16 scenarios (e.g. cleaning the 
house) and participants must rate their fear of falling on a scale 
from 1 (Not at all concerned) to 4 (Very concerned).
Measurement of visual sampling during gait
Participants walked under different environmental (Figure 1) and 
attentional conditions in order to assess the impact of more com-
plex (visual) environments and (cognitive) tasks.
Environmental conditions included; walking straight, walking 
straight through a doorway and turning while walking through 
a doorway (see Figure 1). The visual sampling during gait test-
ing was also repeated with a visual cue in place for the straight 
walks. The visual cue consisted of transverse black tape lines on a 
white floor placed 50cm apart (approx. a ‘normal’ step length) as 
depicted in Figure 1, which participants were asked to step over as 
they complete the walk. A visual cue was used as they are known 
to help ameliorate gait impairments in PD61, which may be due to 
the increased task-related visual information62 or greater attention 
being allocated to gait61.
Attentional conditions included; single task (i.e. just walking) and 
dual task (i.e. repeating numbers while walking based on a maximal 
forward digit span obtained in sitting). A dual task was used as a 
representative of real-world walking, in which carrying out several 
tasks at once is common (i.e. walking and talking)60.
Both groups (PD and controls) performed the same walking condi-
tions (Figure 1); with repeat measures (three trials for each condi-
tion) taken for an average to be created.
Equipment
Visual sampling (the combination of saccades and fixations) was 
assessed with a Dikablis (Ergoneers, Germany) head-mounted 
infra-red eye tracking system, synchronised with a 3D motion 
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capture system (Vicon, Oxford, UK) and an electrooculography 
(EOG) system (Zerowire, Aurion, Italy), to allow for simultaneous 
and comprehensive recording and analysis of gait and eye move-
ment data. Dikablis calibration was performed while standing using 
the manufacturer 4-point procedure for each participant prior to 
data collection. Similar to our previous research29, EOG was also 
calibrated prior to data collection via asking participants to blink 
for 30 secs and move their eyes horizontally between set-distance 
visual targets (5°, 10° and 15°) for 30 secs in time with an auditory 
cue (a metronome beat) while seated.
The Dikablis eye-tracker recorded eye movement using an infra-red 
camera63–65, this data was combined with EOG data which involves 
two small electrodes being applied bi-temporally on the forehead of 
the participant. Importantly, the Dikablis has an adequate sampling 
frequency (50Hz) to detect saccades during gait66,67 and EOG has a 
high sampling frequency (1000Hz) which allows accurate acquisi-
tion of specific visual sampling characteristics such as velocity, accel-
eration, distance etc.15. The Dikablis device includes two aspects; a 
head unit and a transmitter bag. Both the head unit (approx. the same 
size as a pair of glasses) and the bag (approx. 1kg) are lightweight. 
The head unit was taped, with a small amount of double sided tape, 
to the forehead of the participants to prevent error due to slippage. 
Eye movement data from the Dikablis was collected at 50Hz and 
from the EOG system at 1000Hz; this was saved onto a computer to 
be analysed using proprietary software66.
Video recording and the Vicon 3D motion capture system recorded 
participants movement during walking using a camcorder and 
infra-red sensors attached to the skin of the participants at specific 
locations (Figure 2; 2× shoulders, 1× sternum, 2× anterior superior 
iliac spine (ASIS), 2× posterior superior iliac spine (PSIS), 2× big toe, 
2× instep, 2× heel and 4× head) using a small amount of double 
sided tape. Participants were required to bring their own shorts and 
a vest to wear in order for the markers to be placed onto the appro-
priate body locations. Vicon 3D motion analysis is a valid and reli-
able method of assessing the spatiotemporal parameters of gait in 
older adults and in people with PD68.
Accuracy and reliability testing of visual sampling
Mobile infra-red eye-tracking and EOG have been shown to be a 
valid and reliable method for assessing saccadic activity in younger 
adults69, and both have previously been used in older adults and 
in people with PD29,70–73. We were interested in the accuracy and 
test-retest reliability of mobile eye-tracking in people with PD and 
older adult controls to ensure the robustness of data interpretation. 
Therefore, a subgroup (PD and control; up to n=25) were asked 
to return approx. one week later for a second and third visit for 
accuracy and test re-test reliability testing (Table 2). The Dikablis 
eye-tracker recorded eye movement and was used in the same man-
ner as the previous study63–65, combined with video recording of 
individuals body movement and a tri-axial accelerometer (Axivitiy, 
AX3, York, UK) recording head movement.
In the second session the sub-group of participants were asked 
to repeat the walking tasks from session 1 (single task, without a 
visual cue) to provide visual sampling during gait reliability data. 
Accuracy of visual sampling measurement was determined by ask-
ing participants to sit (with chin rest in situ), stand (without moving 
their head) and walk (free head movement) on a treadmill, while 
performing several eye movements to visual targets (horizontal 
and vertical visual angles such as 5°, 10°, 15°) in time with an 
Figure 1. Walking conditions.
Straight Left turn with door Straight with door Right turn with door Straight with cue Straight with cue and door
2m
0.5m
0.8m
2.5m
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Figure 2. Reflective marker body placement locations.
auditory cue (a metronome). The subgroup was asked to return for 
a third visit (within approx. 1 week of the second visit) to repeat the 
accuracy testing (as above) in order to derive test-retest reliability 
results.
Primary outcome measure
Saccade frequency during gait
The primary outcome measure was saccade frequency (number 
of fast eye movements per second when walking) during gait, 
which was recorded via the Dikablis mobile eye-tracker and EOG 
systems.
Secondary outcome measures
Visual sampling. Secondary visual sampling outcomes included: 
saccade number, velocity, acceleration, amplitude and duration, as 
well as fixation number and duration.
Gait characteristics. Gait characteristics were measured via video 
recording and a Vicon 3D motion capture system for all walking 
conditions in order to examine associations between cognitive and 
visual functions and gait, and saccadic frequency and gait (Figure 1). 
Spatiotemporal gait characteristics included step velocity, step 
length, step time, single support time and double support time, 
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which were chosen because they have been selectively associated 
with cognitive74 and visual functions75,76 in people with PD and 
older adults in previous research.
Safety considerations. All measurements were non-invasive and 
placed the participant at no risk other than those that normally 
may occur during walking. To prevent excessive fatigue, partici-
pants were encouraged to take breaks as needed throughout all 
study procedures. The hypoallergenic double-sided tape used to fix 
the infra-red markers and Dikablis head unit onto the skin of the 
participants did not cause any adverse effects. The amount of tape 
was small and it has been used on numerous occasions in other 
research projects at the CARU and no issues have been reported. 
The bi-temporal EOG electrodes also did not cause any adverse 
effects. The treadmill used within the accuracy and reliability test-
ing was equipped with a safety harness to avoid any falls-related 
injuries, as the harness could support the participant and trigger the 
treadmill to automatically stop in the event of a fall.
Ethical approval. Ethical approval for this project was obtained from 
the NRES Committee North East -Newcastle and North Tyneside 
1 Research Ethics Committee (approved 6th June 2013, Reference 
13/NE/0128). Written informed consent was obtained for every 
participant prior to testing. The study began 1st July 2013.
Dissemination. Data collection for the study finished in July 2015 
and results will be published within peer reviewed scientific jour-
nals, open-access publication will be preferred. A public engage-
ment event will also be used to disseminate findings to participants 
and public. All participants were assigned participant numbers, 
allowing data to be anonymised and reported confidentially. 
All results from the study will be uploaded to Clinicaltrails.gov 
(ID: NCT02610634) once analysed. No contractual agreement lim-
its access to data.
Statistical analysis
Sample size
This was an exploratory study and therefore few specific previous 
examples were available to guide estimates for sample size. We have 
based the estimate (≥40 participants in each group) on our previous 
work (PD; n=21)29 and other previous similar studies. Similar studies 
in this research area72,73,77–80 have used small sample sizes (n=2–26) 
and reported between-group differences, demonstrating that we 
will be able to see differences between our sizable PD and control 
Table 2. Study protocol overview.
Participants (n = 100) Session 1 (up to 150min) Session 2 (up to 60min) Session 3 (up to 60min)
1. Older adult controls 
(n = 40)
2. Parkinson’s disease 
(n = 60)
Applicable to all participants 
(n=100)
• Initial screening, cognitive and 
visual function assessments 
(45–60min)
• Informed consent
• Demographic and diagnostic 
evaluation
Global cognitive assessments:
    • MoCA
    • ACE-R
Specific cognitive domain 
assessment:
    • JLO
    • CLOX 1 and 2
    • VOSP battery
    • Attention CDR battery
Visual function assessments:
    • Visual acuity
    • Contrast sensitivity
PD-Specific assessments:
    • UPDRS
    • Hoehn and Yahr
    • FOG-questionnaire
Common assessments:
    • GDS-15
    • FES-I
Visual sampling during gait 
testing in gait laboratory 
(60–90min)
Applicable; for a subgroup of PD 
and control participants (n=25) 
Approx. 1 week after session 1 
1st Reliability testing (45–60min)
    • Repeat visual sampling during 
gait testing in gait laboratory (single 
task, without a visual cue)
    • Sit, stand and walk on a 
treadmill while making eye-
movements to set distance targets 
(5°, 10° and 15°)
Applicable; for a subgroup of PD 
and control participants (n=25) 
Approx. 1 week after session 2 
2nd Reliability testing (45–60min)
    • Sit, stand and walk on a 
treadmill while making eye-
movements to set distance targets 
(5°, 10° and 15°)
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groups. It is a general recommendation to include 30 cases per group 
to be able to carry out basic statistical tests (e.g. between group 
comparisons)81. This study will inform future power calculations.
Data analysis will follow a predetermined plan:
Analysis common to all studies
Statistical analysis will be undertaken using SPSS version 22 
(SPPS, Inc. an IBM company). Demographic characteristics and 
baseline data will be summarized using descriptive statistics, includ-
ing means, standard deviations, median, minimum, maximum and 
inter-quartile ranges for continuous or ordinal data and percentages 
for categorical data. The descriptive statistics will be tabulated and 
presented graphically for clarity. One-sample Kolmogorov-Smirnov 
tests will be used to check for normally distributed data. Non-
normally distributed continuous distributions will be transformed 
where appropriate to meet the requirements of parametric tests; 
otherwise equivalent non-parametric tests will be adopted. Data will 
also be assessed graphically (such as histograms or scatter plots) for 
clarity of information. As this is an exploratory study a threshold of 
p < .05 (two-sided) will guide statistical interpretation.
Further analysis
To analyse visual sampling during gait, a series of mixed analysis 
of variance (ANOVA) will be used with effect of PD (PD and 
control) as between participant factor and attention (single task, 
dual task) and environment (Straight walk, Door, Turn) as within 
group factors. Pearson’s correlations will be used to test the strength 
and direction of the relationships between clinical, gait and saccade 
frequency outcomes. Gait characteristics will also be assessed with 
the same mixed ANOVA method.
To test the effect of visual cueing on visual sampling and gait; a 
mixed ANOVA will be used with group (PD and control), visual cue 
(no cue and cue) and attention (single task, dual task). Comparison 
with and without a visual cue will also be made via the same mixed 
ANOVA for the various gait characteristics, while controlling for 
the influence height.
Associations between cognitive and visual functions will be made 
using Pearson correlations. Cognitive and visual function contribu-
tion to visual sampling will be assessed using multiple regression 
analysis, while controlling for demographic factors (age, motor 
severity, depression, global cognition).
To analyse reliability; repeated-measure t-tests, Bland and Altman 
plots, intra-class correlation coefficients (Model 2, 1) and Pearson’s 
correlations (or non-parametric equivalents) will be used to assess 
bias, absolute and relative agreement and consistency of saccadic 
outcomes measured with the Dikablis eye-tracker on two separate 
occasions a week apart. A similar statistical approach will be used 
to assess accuracy of the Dikablis system against targets of a known 
angle (5°, 10° and 15°).
Discussion
The aims of this study were to provide a greater understanding of 
the roles that cognition and vision play in gait in PD. Specifically 
this study provided data regarding the role that visuo-cognition 
plays in gait in PD, as well as relationships between cognitive and 
visual functions (termed visuo-cognition). What sets this project 
apart from other work in this field is that the study is taking into 
consideration the combined and interactive impact that cognitive 
and visual function impairments have on gait in PD.
The study protocol was developed in response to recently reviewed 
evidence and study recommendations for visual sampling during 
a dynamic motor task15. The protocol focussed not only on cog-
nitive impairments but also visual dysfunction which is commonly 
reported in PD and until now has not been fully investigated. Little 
quantitative data has been previously reported regarding visual 
sampling during real-world tasks (e.g. gait, reaching etc.) in PD 
and the few previous studies available only involve small cohorts 
often performing simple static motor tasks (i.e. mouse clicks or 
button pressing or reaching82,83).
This study investigated the online visuo-cognitive behavioural 
measure of visual sampling during a real-world task (i.e. gait), and 
data analysis will examine interaction between visual sampling, 
cognitive and visual functions and task performance. The study will 
determine the influence of cognitive and visual functions on visual 
sampling during gait and gait characteristics in PD. This will allow 
us to determine whether gait impairments in PD are influenced by 
basic visual function (CS and VA) impairment or cognitive impair-
ment (particularly attention) or a combination of these aspects.
Finally, an important feature of this study is that it is expected to 
provide the first evidence on the accuracy and reliability of using 
mobile eye-tracking equipment during gait with older adults and 
people with PD, which will develop the standard of research being 
conducted in this area and allow for more definitive conclusions.
Conclusion
This exploratory observational study will assist with understanding 
the role that cognition and vision play in gait in PD and how com-
bined visuo-cognitive processes influence gait outcomes. In addition, 
it will provide evidence on the interaction between cognitive and 
visual functions in PD, as well as how visual sampling during gait is 
affected by the use of clinical interventions such as visual cues.
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